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Informed Consent and Approval 
by Institutional Review Boards 
in Published Reports on Clinical Trials
 
To the Editor:
 
 Publication of the results of biomedical re-
search is not a mere formality in science. It is the culmi-
nation of a long process, and careful attention to every
step in that process is important.
 
1
 
 In randomized clinical
trials, failing to obtain or forgetting to report informed
consent from participants or approval of the protocol by
an institutional review board (IRB) might suggest that the
authors considered these steps unimportant details, if not
obstacles. This is clearly a misconception, because the aim
of research is to serve human subjects, not to use them.
We assessed the frequency of reporting of informed
consent and IRB approval in all reports of trials published
between 1993 and 1995 in the 
 
New England Journal of
Medicine,
 
 the 
 
Lancet,
 
 the 
 
Journal of the American Medical
Association,
 
 and the 
 
British Medical Journal.
 
 We also
searched the Medline data base for all trials with at least
one author from Spain that were published in other jour-
nals during the period from 1993 to 1995. We included
all reports of trials involving human subjects that had two
or more treatment groups and studies referred to as “clin-
ical trials,” “field trials,” or “randomized trials” by the au-
thors. When information on IRB approval or informed
consent was missing in the reports, we mailed a standard-
ized questionnaire to the corresponding authors. After
two months, we repeated the mailing for authors who had
not responded to the first questionnaire.
Of reports on 767 clinical trials, 543 (70.8 percent)
stated that an IRB had approved the research, and 612
(79.8 percent) reported that informed consent had been
requested from the participants. Both types of information
were included in 64 percent of the reports. The authors
explicitly stated that they had not requested the informed
consent in 10 reports. In all these trials, the authors re-
ported having obtained IRB approval. Many of these trials
were studies of cardiopulmonary resuscitation for patients
with cardiac arrest.
The response rate for authors of reports that lacked in-
formation on IRB approval was 73.7 percent (165 of
224), and the rate for authors of reports that lacked infor-
mation on informed consent was 70.3 percent (102 of
145). Thirty-seven of the 165 respondents who did not re-
port on IRB approval (22.4 percent) stated that they had
not sought approval, and 21 of the 102 who did not re-
port on informed consent (20.6 percent) stated that they
had not requested informed consent.
There were no significant differences in the proportion
of reports that included information on IRB approval or
informed consent according to the year of the survey or the
number of participating centers. We constructed a logistic-
regression model with failure to disclose either IRB approv-
al or informed consent as the outcome (Table 1). Among
other findings, reports published in the 
 
New England Jour-
nal of Medicine
 
 as compared with other journals, those
with authors from European countries (excluding Spain and
the United Kingdom) as compared with other countries,
and those involving trials funded by the pharmaceutical
industry as compared with other sources of funding were
more likely to report IRB approval or informed consent.
Similar surveys have been reported elsewhere.
 
2-5
 
 They
assessed a smaller number of trials (range, 37 to 279). In
general, our survey showed a higher rate of reporting of IRB
approval and informed consent than the other surveys did.
However, our results suggest that, even in the leading gen-
eral medical journals, closer attention to the conduct of
clinical research, as well as the reporting of its ethical aspects,
is needed.
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Pravastatin and Coronary Heart Disease
 
To the Editor:
 
 The Long-Term Intervention with Prava-
statin in Ischaemic Disease (LIPID) trial (Nov. 5 issue)
 
1
 
 is
the third study, after the Scandinavian Simvastatin Survival
Study
 
2
 
 and the Cholesterol and Recurrent Events study,
 
3
 
on the use of 3-hydroxy-3-methylglutaryl–coenzyme A re-
ductase inhibitors for secondary prevention of coronary
disease. The positive results of this trial are as marginal as
those of the studies that preceded it.
The authors calculated relatively high values for risk re-
 
*Trials whose authors originally acknowledged not having obtained IRB approval or informed consent are included
with trials whose authors did not originally disclose information about these issues. For comparisons of the failure to
disclose information on one or both issues, the percentages of authors who failed to report on both must be added to
the percentages of authors who failed to report on one.
†A higher odds ratio (OR) means a higher probability of failing to provide information about either or both issues in
the original report. Odds ratios have been adjusted (by logistic regression) for all variables shown in the table and also
for the length of the article and the methodologic characteristics of the trial. CI denotes confidence interval.
‡This was the reference category.
§There were 103 other journals that published reports with authors from Spain. The most frequently reviewed journals
in this group (and the number of trials included in the study) were 
 
Hepatology 
 
(12 trials), 
 
Gut
 
 (6), the 
 
Journal of Hepa-
tology
 
 (6), 
 
Antimicrobial Agents and Chemotherapy 
 
(3), the
 
 American Journal of Hypertension
 
 (3), 
 
Annals of Oncology
 
 (3),
 
Intensive Care Medicine
 
 (3), and the 
 
Journal of Pharmacology and Experimental Therapy
 
 (3).
¶In the case of international trials, the country (or group of countries) was assigned according to the following order:
Spain, the United States, the United Kingdom, other European countries, and other. For example, a trial with Spanish
participation was assigned to Spain, and a collaborative American–British trial was assigned to the United States.
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percent
 
All trials 767 12.9 16.3 6.9
Journal
 
New England Journal of Medicine
 
‡ 219 4.1 14.2 3.7 1.00
 
Journal of the American Medical 
Association
 
81 9.9 8.6 11.1 1.72 (0.89–3.30)
 
British Medical Journal
 
105 21.0 24.8 9.5 4.74 (2.31–9.74)
 
Lancet
 
203 11.8 13.8 8.9 2.15 (1.21–3.83)
Other journals (with Spanish 
authors)§
159 22.6 20.8 5.0 1.78 (0.65–4.92)
Country of authors¶
Europe (except United Kingdom 
and Spain)‡
136 8.8 11.8 4.4 1.00
Spain 187 20.9 20.3 5.3 4.14 (1.53–11.20)
United Kingdom 127 18.1 19.7 9.4 2.33 (1.26–4.30)
United States 240 7.1 13.3 8.3 2.49 (1.30–4.74)
Other 77 10.4 18.2 6.5 2.44 (1.21–4.91)
No. of subjects in trial
«50‡ 196 15.8 12.8 4.1 1.00
51–500 399 10.5 18.3 7.0 1.61 (1.00–2.59)
501–2000 116 13.8 18.1 8.6 2.77 (1.43–5.38)
>2000 56 17.9 10.7 12.5 2.14 (0.93–4.97)
End point
Efficacy‡ 554 11.4 17.9 6.0 1.00
Pharmacologic end point 59 10.2 8.5 5.1 0.44 (0.20–0.95)
Safety 37 13.5 10.8 2.7 0.74 (0.32–1.71)
Prevention 75 18.7 10.7 10.7 0.93 (0.50–1.74)
Diagnostic or other end point 42 26.2 21.4 19.0 1.76 (0.79–3.93)
Source of funding
Pharmaceutical industry‡ 225 7.1 8.0 7.1 1.00
Public agency 199 13.6 18.6 9.5 1.38 (0.80–2.37)
Other 143 7.0 17.5 9.1 1.71 (1.04–2.81)
Not reported 200 23.0 22.5 2.5 2.13 (1.25–3.62)
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duction with pravastatin as compared with placebo, those
being between 11 and 23 percent, which might tempt the
inexperienced physician to use statins universally. The rel-
evant values with respect to the reduction of events are,
however, much lower and demonstrate a small treatment
effect. However, the data on the “number needed to treat”
are the most informative for the expert. It can be deduced,
for example, that 316 patients have to be treated in order for
one coronary event to be averted in 1 patient. Yet, 315 pa-
tients would be burdened with a medication, the dangers
of which cannot be foreseen in the case of treatment over
a period of 20 to 30 years. Pravastatin has no particular ad-
vantage over placebo, even for certain subgroups at higher
risk (those »70 years of age and those with hypertension,
diabetes, or total cholesterol levels »251 mg per deciliter).
The optimistic conclusion of the authors that “the cur-
rent low rate of use of cholesterol-lowering therapy among
patients with CHD [coronary heart disease] can no longer
be accepted” is not defensible when the appropriate meas-
ures (reduction of events and number needed to treat) are
considered. Incidentally, Krumholz et al.
 
4
 
 already called for
patients over 70 years of age not to be burdened with lipid-
lowering agents, and Weverling-Rijnsburger et al.
 
5
 
 dem-
onstrated that, in the case of the very elderly, life expect-
ancy shows a positive correlation with cholesterol values.
Healthful living, a varied diet, physical activity, not smok-
ing, and adequate social integration are of greater use than
statins for increasing life expectancy. Statins are rather
fragile props.
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To the Editor:
 
 The LIPID Study Group concludes, “The
current low rate of use of cholesterol-lowering therapy
among patients with CHD can no longer be accepted”;
however, less than 50 percent of the patients in their study
received 
 
b
 
-adrenergic blockers. No comment was made
about this fact. Beta-blocker therapy effectively reduces the
incidence of myocardial infarction in patients with coro-
nary artery disease,
 
1
 
 yet many patients for whom beta-
blocker therapy would be ideal are not prescribed these
drugs at the time of their discharge from the hospital after
acute myocardial infarction.
 
2
 
Given that pravastatin is much more expensive than
beta-blockers and aspirin and that cost constraints are a
concern, we ought to try aspirin and beta-blockers before
we prescribe a 3-hydroxy-3-methylglutaryl–coenzyme A
reductase inhibitor.
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National use and effectiveness of 
 
b
 
-blockers for the treatment of elderly pa-
tients after acute myocardial infarction. JAMA 1998;280:623-9.
 
The authors reply:
 
To the Editor:
 
 In the LIPID trial of patients with CHD,
we studied the effects of pravastatin used with dietary advice
and usual care, including myocardial revascularization and
drugs such as beta-blockers and aspirin. Similar benefits of
pravastatin treatment were seen in those who received
beta-blockers and those who did not. Among the 4229
patients receiving beta-blockers at the time of study entry,
pravastatin therapy resulted in a 19 percent reduction in
coronary events (P=0.01), a 29 percent reduction in mor-
tality from CHD (P=0.004), and a 30 percent reduction in
total mortality (P<0.001) as compared with placebo. Con-
sequently, the benefits of pravastatin should be regarded
as additional to any benefits of beta-blocker therapy.
The cost effectiveness of pravastatin is the subject of a
separate report, but a preliminary analysis has shown this
treatment to be cost effective, as compared with other ac-
cepted medical interventions. The cost is less than $6,300
($10,000 Australian) for each year of life gained.
In response to the comments of Meyer: the LIPID trial
extends the results of the Scandinavian Simvastatin Surviv-
al Study and the Cholesterol and Recurrent Events study
in important ways. The results of the LIPID trial provide
convincing evidence of a treatment effect on total mortal-
ity in patients with CHD and typical cholesterol levels. Al-
though the size of the treatment effect is moderate, with
an absolute reduction in mortality of 3.1 percent over 6.1
years, this rate means that 32 patients need to be treated
over this period in order for one death to be prevented. If
serious nonfatal events (myocardial infarction or stroke) are
also considered, only 15 patients need to be treated over
6.1 years in order for one serious fatal or nonfatal event to
be prevented. For a treatment with no demonstrated seri-
ous side effects and a long-term record of safety, this rep-
resents substantial clinical benefit.
The LIPID trial did not have the power to demonstrate
reliable separate treatment effects for women, the elderly,
or patients with diabetes. However, the results were con-
sistent, with a similar relative reduction in CHD events for
each of the prespecified subgroups. Assuming the same
relative reduction, a larger absolute benefit will result for
those in groups at higher risk. This is particularly so when
the patients in the LIPID trial are compared with popula-
tions without CHD and those with
 
1
 
 or without
 
2
 
 elevated
cholesterol levels. In fact, larger benefits can be expected
from the treatment of patients with CHD and average
cholesterol levels than from the treatment of those with-
out CHD but with elevated cholesterol levels.
We accept that the LIPID study has not ruled out the
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possibility of long-term complications associated with treat-
ment over the course of decades. We continue to follow
the entire LIPID cohort, with approximately 85 percent
of the patients continuing to receive pravastatin therapy.
We plan to analyze results after a further two years of fol-
low-up and again after five years.
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Melbourne, Victoria 3003, Australia
 
D
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Royal Melbourne Hospital
Parkville, Victoria 3050, Australia
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University of Sydney
Sydney, NSW 2006, Australia
FOR THE LIPID STUDY GROUP
1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart dis-
ease with pravastatin in men with hypercholesterolemia. N Engl J Med 
1995;333:1301-7.
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute cor-
onary events with lovastatin in men and women with average cholesterol 
levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
Implantable Defibrillators, Pacemakers,
and Electronic Antitheft Devices
To the Editor: The report by Santucci et al. (Nov. 5 is-
sue)1 provides another example of sources of interference
with implantable defibrillators.2 That this should occur is
not surprising to anyone familiar with the sensing function
of medical devices. Indeed, such systems have been falsely
triggered by devices such as radio-controlled model cars
and slot machines,3 electrocautery for unrelated surgery,
and neural stimulators for pain control. Other devices and
procedures that may be expected to inhibit the output of
pacemakers or initiate inappropriate discharge of defibrilla-
tors include hair-removal (depilation) units and rapid-stim-
ulation electromyography studies. In two patients with im-
plantable cardioverter–defibrillators who were treated at
my facility, the devices discharged while they were jump-
starting a car with battery cables.
That such events may occur is not in question; up to 20
percent of all firings of implantable cardioverter–defibril-
lators are estimated to be inappropriate. However, readers
should not interpret isolated case reports as representing a
trend, and patients can take comfort in the infrequency
with which such externally triggered events apparently oc-
cur. The reality is that several hundred thousand recipients
of medical devices pass through electronic antitheft sys-
tems each day, yet there are but a handful of documented
episodes of interference. Of the hundreds of thousands of
Holter-monitoring studies performed each year, many in
patients with implanted cardiac devices, the occurrence of
such interference is all but unknown. Although it is easy to
have discussions of who is responsible for minimizing such
interactions (the electronic-field producer or the implant-
ed-device producer),2 a simple technical solution is elusive.
“Don’t linger, don’t lean” is an easy, practical remedy that
was recently recommended by the Food and Drug Admin-
istration (FDA),4 and the American Heart Association has
made similar recommendations.
In the same issue of the Journal, Drs. McIvor and Srid-
har5 report on interactions between cardiac pacemakers and
antishoplifting security systems. In Figure 1 of their re-
port, the first two native QRS complexes suggest that the
patient is in atrial flutter, which if sensed, can initiate pac-
ing at the upper tracking rate of the device. The recorded
rhythm strip is 18 seconds long, and, contrary to what is
implied in the figure, it seems unlikely that the patient
walked through the gate. An elderly person on crutches
could navigate this space in half the time.
Each of us in the field of device therapy must take notice
of such reports and strive to confirm the absence of any
clinically significant consequences. The average patient,
when passing through such a system, is exposed to the sig-
nal source for a period that is equivalent to one or two heart-
beats, and little more than transient extra heartbeats or
skipped beats have been demonstrated in response in prior
studies.
The innovative therapies of cardiac pacing and defibril-
lator therapy have provided lifesaving benefits to hundreds
of thousands of patients in the 40 years since the first pace-
maker was installed. In the final analysis, all such patients
can and should be encouraged to lead normal lives and to
act with prudence during exposure to societal sources of
electromagnetic interference.
J. WARREN HARTHORNE, M.D.
Massachusetts General Hospital
Boston, MA 02114-2696
1. Santucci PA, Haw J, Trohman RG, Pinski SL. Interference with an im-
plantable defibrillator by an electronic antitheft-surveillance device. N Engl 
J Med 1998;339:1371-4.
2. Irnich W. Electromagnetic interference in current implantable devices. 
In: Vardas PE, ed. Cardiac arrhythmias, pacing & electrophysiology: the 
expert view. Dordrecht, the Netherlands: Kluwer Academic, 1998:427-36.
3. Madrid AH, Moro C, Martín J. Interference of the implantable defib-
rillators caused by slot machines. Pacing Clin Electrophysiol 1996;19:675. 
abstract.
4. Important information on anti-theft and metal detector systems and 
pacemakers, ICDs, and spinal-cord stimulators. Rockville, Md.: Center for 
Devices and Radiological Health, September 28, 1998. (Or see: http://
www.fda.gov/cdrh/safety/easnote.html.)
5. McIvor ME, Sridhar S. Interactions between cardiac pacemakers and 
antishoplifting security systems. N Engl J Med 1998;339:1394-5.
To the Editor: We commend Santucci et al. for their dis-
cussion of the effects of electromagnetic interference on
the activity of implantable cardioverter–defibrillators. How-
ever, we disagree with their assertion that clinical problems
caused by electromagnetic interference with implantable
defibrillators are rare and without life-threatening conse-
quences. We are aware of cases in the literature and in our
own experience in which electromagnetic interference in
the perioperative environment has had potentially life-
threatening ramifications.1,2
More than 500,000 patients in the United States have
implantable cardioverter–defibrillators or pacer–cardio-
verter–defibrillators, and more than 40,000 are at risk for
sudden death from malignant tachyarrhythmias. These de-
vices are implanted in patients with severe, irreversible, struc-
tural heart disease with compromised myocardium. Many
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of these patients who are highly dependent on the proper
functioning of the devices are exposed to electromagnetic
interference in the perioperative environment.
Santucci et al. correctly point out that electromagnetic
interference is rarely life threatening in most settings, but
in the highly electromagnetic-interference–contaminated
perioperative environment, patients may be at serious risk.
Perioperatively, the sources of electromagnetic interference
include surgical electrocautery, extracorporeal shock-wave
lithotripsy, nuclear magnetic resonance imaging, high-
voltage electrical devices, and radiotherapy for nondiag-
nostic purposes. Electromagnetic interference “noise” may
have several undesirable consequences: inappropriate ther-
apy, since electromagnetic interference may be identified as
arrhythmia, stimulating dangerous tachyarrhythmias; chang-
es in programming, since electromagnetic interference may
be misinterpreted, altering algorithms for detection and
treatment; and damage to circuitry, leads, or electrodes,
rendering the device inoperable and causing permanent
myocardial damage.3
All U.S. manufacturers of implantable cardioverter–
defibrillators and pacer–cardioverter–defibrillators recom-
mend that the devices be disabled (that antitachycardia and
other functions be suspended) at a pacemaker clinic or by
a technician if patients are to be exposed to electromag-
netic interference perioperatively. Positioning a strong mag-
net over the pulse generator will temporarily suspend the
automatic-detection and therapeutic capabilities of the
device. Other suggestions include keeping a grounding pad
15 cm from the site of electromagnetic interference, ori-
enting external defibrillator pads away from the pulse gen-
erator,4 avoiding diathermy in favor of bipolar cautery,
careful monitoring of the pulse wave form and electrocar-
diogram, and remaining prepared to perform external con-
version and cardiac resuscitation.5
Currently, despite the diversity and complexity of these
devices, among the 10 U.S. manufacturers, there are no in-
dustry-wide guidelines for perioperative malfunction. To
ensure the safety of patients, universal and practical solu-
tions for perioperative management of implantable cardio-
verter–defibrillators and pacer–cardioverter–defibrillators
should be developed by the appropriate clinical specialties
in conjunction with the manufacturers.
PAUL BARACH, M.D., M.P.H.
Massachusetts General Hospital
Boston, MA 02114
ERIC BAUM, B.S., C.E.N.
University of Florida
Gainesville, FL 33186
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The authors reply:
To the Editor: We agree with Dr. Harthorne that reports
of inappropriate discharge of implantable cardioverter–
defibrillators should not come as a surprise to anyone fa-
miliar with these devices. Although up to 20 percent of fir-
ings may be inappropriate, a very small percentage are
caused by external electromagnetic interference. Clinically
minor sequelae of electromagnetic interference in patients
with pacemakers and implantable cardioverter–defibrilla-
tors have been described from a variety of sources. The in-
tent of our report was to bring attention to the potential
for such interactions to be serious and to alert patients,
physicians, and the industry to the possibility of a severe
interaction between implantable cardioverter–defibrillators
and at least one type of electronic antitheft-surveillance
unit. It was our impression that the potential seriousness of
such interactions, although they are rare, was not known
or widely anticipated and that patients were not routinely
made aware of this phenomenon or informed of the simple
method of prevention. Recently, Dr. Harthorne properly
noted that no serious interactions had previously been
documented between antishoplifting equipment and im-
plantable cardioverter–defibrillators.1
Our recommendations were straightforward and in con-
cordance with those of the FDA and American Heart As-
sociation. Specifically, the avoidance of prolonged expo-
sure to antitheft equipment should minimize or eliminate
problems. Since our report, several anecdotal reports of
interactions between pacemakers and implantable cardio-
verter–defibrillators and antitheft equipment have been
brought to our attention. Although it is not our intent to
frighten patients unnecessarily, such interactions may not
be as rare as previously thought, and we suspect they have
been underreported. We believe that it is appropriate rou-
tinely to inform patients of the possibility of such an in-
teraction and of the appropriate means to avoid it. This
should be done in a reassuring manner, to avoid unneces-
sary psychological effects. It is only through a lack of aware-
ness that more patients are likely to experience such events.
Dr. Barach and Mr. Baum correctly point out that elec-
tromagnetic interference in the hospital environment is a
common cause of inappropriate functioning of pacemakers
and implantable cardioverter–defibrillators. We have previ-
ously described common sources of electromagnetic inter-
ference in hospitals and the workplace.2,3 It is therefore pre-
operative routine in most institutions to take precautions
such as those described to avoid undesirable effects, which
can certainly otherwise be life threatening. Electromagnetic
interference is a rare cause of serious interference during
routine daily life. Fortunately, most of these interactions can
be prevented by appropriate awareness and planning.
PETER A. SANTUCCI, M.D.
SERGIO L. PINSKI, M.D.
RICHARD G. TROHMAN, M.D.
Rush–Presbyterian–St. Luke’s Medical Center
Chicago, IL 60612
1. Harthorne JW. Theft deterrent systems: a threat for medical device recip-
ients or an industry cat fight? Pacing Clin Electrophysiol 1998;21:1845-6.
2. Pinski SL, Trohman RG. Implantable cardioverter-defibrillators: impli-
cations for the nonelectrophysiologist. Ann Intern Med 1995;122:770-7.
3. Idem. More on patients with implantable cardioverter-defibrillators. 
Ann Intern Med 1995;123:893.
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To the Editor: The myriad sources of electromagnetic ra-
diation that can interfere with implanted medical devices
have been recognized for quite some time.1 Our interest
in electronic article surveillance systems, or antishoplifting
gates, dates to the experience of one of our patients, who
had an inappropriate discharge of her implantable cardio-
verter–defibrillator while standing next to such a system
in a store.2 Our findings have since been confirmed.3,4 The
largest formal test of implantable cardioverter–defibril-
lators, whose results were presented to the FDA in Sep-
tember 1998, suggested that 1 in 50 patients will have an
inappropriate firing of their implantable cardioverter–
defibrillator when exposed to the field of an acousto-
magnetic electronic article surveillance system. Whether a
2 percent incidence of inappropriate firings is clinically sig-
nificant depends on one’s point of view. There is no need
to cause a panic among the 98 percent who will not be
affected, but by educating patients not to linger in these
fields, we can eliminate the problem altogether. Because
such systems can be concealed behind walls or under
flooring, we would also be in favor of advisory signs alert-
ing patients not to linger in areas near these systems.
In our study of patients with implanted pacemakers,5
virtually all interactions were confined to the strong, low-
frequency, pulsed magnetic field generated by the acous-
tomagnetic type of system. Therefore, other types of sys-
tems may not need warning signs. We agree with Dr.
Harthorne about the soundness of a “don’t linger, don’t
lean” approach, since walking quickly through an acousto-
magnetic electronic article surveillance gate (rather than
pausing within or near the system) was associated with a
large decrease in pacemaker interactions (from 96 percent
to 16 percent). Most patients who are passing through
such a system will not be actively using their pacing system
at the time, so few will have symptoms, even if interactions
occur. Others have a potential for interactions, some of
which may cause symptoms. One type of pacemaker gen-
erator can even be reprogrammed by these systems, result-
ing in a faster base-line pacing rate.
It should now be accepted that interactions between
such systems and implanted medical devices occur and are
common in patients with pacemakers. What can be argued
is whether enough patients are adversely affected to war-
rant concern. Our position is that the likelihood of clinical
harm — even for the unlucky few who are at risk — can
be virtually eliminated by proper education of patients.
MICHAEL E. MCIVOR, M.D.
Heart Institute of St. Petersburg
St. Petersburg, FL 33701
S. SRIDHAR, M.D.
Affiliated Cardiologists
Phoenix, AZ 85004
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Management of Acoustic Neuroma
To the Editor: Kondziolka et al. in their study (Nov. 12
issue)1 and Pitts and Jackler in their accompanying edi-
torial2 miss two important issues concerning radiosurgery
for acoustic neuromas. First, since the age of the patient is
relevant to the decision about treatment, a more detailed
analysis of age is required. We and a number of others rec-
ommend observation, not surgery, for patients over the
age of 65 years with acoustic neuromas that are not caus-
ing distortion of the brain stem. Imaging is repeated as
necessary, depending on the size of the tumor, and most
of these older patients never require any intervention —
either surgery or radiosurgery. In patients over 65 with
acoustic neuromas, the issue is not whether radiosurgery
is better than conventional surgery but whether any ther-
apy is necessary. Second, the size of the tumor is very im-
portant. Kondziolka et al. do not give enough information
about tumor size or about how the diameter of a tumor
was determined, and no information correlating size and
age was provided.
ROBERT W. BROAD, M.D.
University of Alberta Skull Base Centre
Edmonton, AB T6G 2B7, Canada
1. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-
term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 
1998;339:1426-33.
2. Pitts LH, Jackler RK. Treatment of acoustic neuromas. N Engl J Med 
1998;339:1471-3.
To the Editor: Although there have been great strides in
radiosurgery, Kondziolka et al. did not discuss how single-
fraction gamma-knife radiosurgery (radiation delivered in
one dose) compares with fractionated treatment. Histori-
cally, radiation has been given in divided doses to mini-
mize damage to normal tissue.
Fractionated stereotactic radiosurgery gives excellent re-
sults, with the same dose used since the inception of this
technique more than five years ago, for acoustic neuromas
from 0.1 to 32 ml in volume and up to 5 cm in diameter,
including those in patients with type 2 neurofibromato-
sis.1-3 Despite the presence of large neuromas and type 2
neurofibromatosis, the preservation rate of the facial and
trigeminal nerves in 142 patients was 100 percent, and 86
percent of the patients retained hearing. With fractionated
radiosurgery, a noninvasive frame for the head obviates the
need for skull pins, anesthesia, sedation, and hospitalization.4
In comparison, gamma-knife radiosurgery caused hear-
ing loss in 49 percent of the patients in the study by
Kondziolka et al., facial neuropathy in 21 percent, and
damage to the trigeminal nerve in 27 percent. Thirty-one
percent of previously employed patients who underwent
gamma-knife radiosurgery became unemployed after the
procedure. Kondziolka et al. report that 18 percent of their
The New England Journal of Medicine 
Downloaded from nejm.org at UNA BIBLIOTECA HUMANIDADES on October 28, 2014. For personal use only. No other uses without permission. 
 Copyright © 1999 Massachusetts Medical Society. All rights reserved. 
1120 · Apr i l  8,  1999
The New England Journal  of  Medicine
patients underwent craniotomy followed by radiosurgery
as primary treatment. This two-step strategy is associated
with greater morbidity, but it makes subsequent single-
fraction radiosurgery appear safer, since the patients will
probably have surgically induced neurologic deficits, such
as hearing loss and facial neuropathy, before radiosurgery.
GIL LEDERMAN, M.D.
EHUD ARBIT, M.D.
JOSEPH LOWRY, M.D.
Staten Island University Hospital
Staten Island, NY 10305
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surg 1997;69:175-82.
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Basel, Switzerland: Karger, 1998:25-30.
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30:599-603.
To the Editor: The article by Kondziolka et al. does little
to define the place radiosurgery may have in the treatment
of acoustic neuromas. The authors claim to have evaluated
162 consecutive patients prospectively over an extended
period of time while frequently changing the criteria for
entry into the study. However, only 38 patients were avail-
able for follow-up at seven to eight years. Have the authors
forgotten that they reported treating no fewer than 134
patients with acoustic tumors between August 17, 1989,
and June 1, 1991?1 Where have all their patients gone?
What they report on is not a group of consecutive patients
but a highly selected sample from a much larger series.
The outcome measure in the study was a change of
±2 mm in tumor size. The detection of such minute
changes would tax the abilities of the most experienced ra-
diologist working under optimal conditions. These tu-
mors were measured by general radiologists at several hos-
pitals with the use of various criteria. It seems highly
implausible that these radiologists could measure tumors
of irregular size, especially recurrent tumors in surgical de-
fects, with the accuracy the study demanded. The authors
failed to validate the interobserver reliability of tumor
mensuration so critical to this study. The doses of radia-
tion used throughout the study varied, and in some in-
stances, even the wishes of the patient determined the
amount of irradiation offered. Given such variation, the
claims made by the authors about the effects of the dose
on therapeutic efficacy are not well founded. The authors’
description of the multivariate analyses does not include
the statistical tests used or even which variables were stud-
ied. Unlike the authors of other quality-of-life studies in
this area,2 the authors failed to use a validated instrument
to determine health status.
The article is less than forthcoming in addressing the
hazards of stereotactic radiosurgery for acoustic tumors.
In particular, the authors do not acknowledge the risk of
cancer known to follow stereotactic radiosurgery. Of the
five patients in the Copenhagen series, cancer developed
in one after radiosurgery.3 Finally, the authors would do
well to remember that acoustic tumors may remain quies-
cent for years and that the rates of “control” attributed to
radiosurgery may be no more than what would have hap-
pened had no treatment been given.
GERARD M. O’DONOGHUE, M.D.
THOMAS NIKOLOPOULOS, M.D., PH.D.
University Hospital
Nottingham NG7 2UH, United Kingdom
JENS THOMSEN, M.D., PH.D.
Gentofte University Hospital
DK-2900 Copenhagen, Denmark
1. Lunsford LD, Linskey ME, Flickinger JC. Stereotactic radiosurgery for 
acoustic nerve sheath tumors. In: Tos M, Thomsen J, eds. Acoustic neuro-
ma. Amsterdam: Kugler, 1992:279-87.
2. Nikolopoulos TP, Johnson I, O’Donoghue GM. Quality of life after 
acoustic neuroma surgery. Laryngoscope 1998;108:1382-5.
3. Thomsen J, Tos M, Borgensen SE, Charabi B. Radiosurgery — a refer-
ring surgeon’s experience. Presented at the European Skull Base Congress, 
London, 1997. abstract.
The authors reply:
To the Editor: Dr. Broad notes the importance of the age
of the patient in selecting a management strategy. As stat-
ed in our article, acoustic tumors in elderly patients are
first managed conservatively with an evaluation of the vol-
ume of the tumor by serial imaging studies. Radiosurgery
is recommended only when clinical progression or tumor
growth has been documented.
The factor of tumor size is also important. As we stated,
tumor size was determined by five separate measurements
performed with the caliper technique, a method we have
described previously.1 Dr. O’Donoghue and colleagues
also missed this statement in our paper. We do not know
why they believe that “tumors were measured by general
radiologists at several hospitals with the use of various cri-
teria,” since this was not stated in our article. All images
were reviewed by our group with the use of the five sepa-
rate measurements with calipers. O’Donoghue et al. also
criticize our failure to use a “validated instrument to de-
termine health status.” Although we did not use their in-
strument, we chose to develop and use one that included
neurologic function and potential complications specific
to radiosurgery.
We agree with O’Donoghue et al. that some acoustic
tumors can remain quiescent for years, although data on
the natural history of acoustic neuroma indicate an average
growth rate of 2 mm per year.2 In our experience, more
than 80 percent of acoustic neuromas followed with serial
images show objective, measurable growth within five years.
However, whether the effect of radiosurgery may be no
different from that of no treatment is an argument that
ended years ago.
We also clearly stated that this study was of a series of
consecutive, unselected patients that included every pa-
tient whose acoustic neuroma was managed with radiosur-
gery at the University of Pittsburgh from August 1987
(when we began) through July 1992. This series allowed
the maximal follow-up of all patients.
Finally, the purpose of our report was to define long-
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term outcomes after radiosurgery, not after fractionated-
radiation therapy. Lederman et al. believe that fractionat-
ed-radiation therapy may offer better tumor control or
neurologic outcomes than gamma-knife radiosurgery. How-
ever, they provide no peer-reviewed comparative data.
The goal of the management of acoustic tumors, wheth-
er with observation, microsurgical resection, stereotactic
radiosurgery, or some other emerging method, is to main-
tain lifelong function. Our systematic evaluation of an un-
selected, consecutive series of patients who underwent ra-
diosurgery during our first 5 to 10 years of using this
technique substantiates the value of stereotactic radiosur-
gery. Anecdotes and small series of patients aside, we await
any comprehensive, long-term evaluation of other treat-
ment strategies.
DOUGLAS KONDZIOLKA, M.D.
L. DADE LUNSFORD, M.D.
JOHN C. FLICKINGER, M.D.
University of Pittsburgh
Pittsburgh, PA 15213-2582
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radiol 1991;12:1165-75.
2. Bederson JB, von Ammon K, Wichmann WW, Yasargil MG. Conserva-
tive treatment of patients with acoustic tumors. Neurosurgery 1991;28:
646-51.
Adrenal Lymphocytic Infiltration
and Adrenocortical Tumors in a Patient
with 21-Hydroxylase Deficiency
To the Editor: Congenital adrenal hyperplasia due to 21-
hydroxylase deficiency results in deficient production of
cortisol and aldosterone, chronic stimulation of the adrenal
cortex by corticotropin, and overproduction of androgens.
Cortisol-replacement therapy often fails to normalize cor-
ticotropin and androgen secretion, and high doses may be
needed.1 Adrenocortical tumors, including cancers, are
rare in patients with 21-hydroxylase deficiency but have been
reported in patients with large adrenal glands and presum-
ably inadequate cortisol therapy.2
A 16-year-old girl with 21-hydroxylase deficiency was
evaluated for hirsutism and primary amenorrhea. She had a
muscular habitus, hyperpigmentation, and a low voice. Phys-
ical examination revealed a beard, cystic acne, and Tanner
stage 2 breast development. While taking 25 mg of hydro-
cortisone and 0.5 mg of fludrocortisone daily, she had high
serum corticotropin, 17-hydroxyprogesterone, and testos-
terone concentrations and high levels of plasma renin ac-
tivity.
Because of persistent, severe symptoms, autonomy of
adrenocortical steroidogenesis, and marked adrenal en-
largement suggestive of tumor formation despite appropri-
ate adjustments in therapy, informed consent was obtained
for bilateral adrenalectomy, and the operation was performed
without complications. Both adrenal glands weighed 52 g
and had a nodular hyperplastic structure. Histologic and
immunohistochemical analyses revealed massive lympho-
cytic infiltration with formation of lymphoid follicles (Fig.
1A and 1B) and diffuse sheets of adrenal cells with com-
pact cytoplasm, an increased mitotic rate, atypical mitotic
Figure 1. Histologic Sections of the Adrenal Cortex of a Patient
with Severe Congenital Adrenal Hyperplasia.
Nodular lymphocytic infiltrates resembling follicles of normal
lymphoid tissue are apparent in Panels A and B (¬50). B lym-
phocytes, immunostained brown with monoclonal antibodies to
CD20 (L26, Dako), are seen mostly in the center of the follicles
(Panel A), whereas T lymphocytes, immunostained brown with
monoclonal antibodies to CD3, are seen in the periphery of the
nodules, spreading into the adrenal tissue (Panel B). Bound an-
tibodies were detected by the linked streptavidin–biotin–per-
oxidase method, and the enzyme reaction was visualized with
3-amino-ethylcarbazole. Panel C shows sheets of large cells
with abundant compact cytoplasm, nuclear pleomorphism, and
hyperchromasia (arrows), which were present throughout both
adrenal glands (hematoxylin and eosin, ¬400).
A
B
C
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figures, and a high nuclear grade suggestive of adrenal car-
cinoma (Fig. 1C). There was no staining for major-histo-
compatibility-complex class II molecules, which is present
in adrenal adenomas but not in carcinomas.3 Subsequent-
ly, while receiving 20 mg of hydrocortisone and 0.5 mg
of fludrocortisone daily, the patient had regular menses,
an increase in breast size, resolution of acne, improvement
of hirsutism and mood, and a decrease in muscle strength
and salt wasting. Two years after surgery, there was no ev-
idence of recurrence.
A major cause of our patient’s adrenal findings was pro-
longed corticotropin stimulation. The lymphocytic infiltra-
tion of her adrenal glands may be a secondary finding;
however, a local lymphocyte–adrenal-cell interaction might
have contributed to her hyperandrogenism and adreno-
cortical growth and histologic signs of carcinoma. Cyto-
kines produced by leukocytes increase adrenal steroid pro-
duction independently of corticotropin.4 Moreover, the
growth of tumor cells may be potentiated by lymphocytes
and cytokines, and aberrant expression of a cytokine re-
ceptor has been implicated in the formation of an adrenal
adenoma.5
Bilateral adrenalectomy was a successful treatment for
this patient and should be considered in patients with con-
genital adrenal hyperplasia with difficult-to-control hyper-
androgenism and large nodular adrenal glands.
DEBORAH P. MERKE, M.D.
STEFAN R. BORNSTEIN, M.D.
DEMETRIOS BRADDOCK, M.D., PH.D.
GEORGE P. CHROUSOS, M.D.
National Institutes of Health
Bethesda, MD 20892
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Gentamicin Contaminated with Endotoxin
To the Editor: A succession of at least 57 moderate-to-
severe endotoxin-like reactions has occurred in the western
United States over an approximately six-month period.
These reactions were associated with the administration of
endotoxin-contaminated gentamicin for injection manu-
factured by Fujisawa USA.1
Endotoxin (a lipopolysaccharide) is a component of the
cell wall of gram-negative bacteria and mediates many of
the clinical features observed in gram-negative bacterial
sepsis. These include fever, shaking chills, and cardiovascu-
lar symptoms, and in more severe cases include muscle
proteolysis, uncontrolled intravascular coagulation, shock,
and death. Endotoxin stimulates mononuclear cells to pro-
duce interleukin-1, tumor necrosis factor a, and possibly
interleukin-6. These cytokines, when administered experi-
mentally to humans, produce symptoms analogous to those
elicited by endotoxin.2
The Food and Drug Administration (FDA) acknowl-
edged the presence of endotoxin in Fujisawa’s gentamicin
early on. However, the concentration of endotoxin was with-
in United States Pharmacopeia (USP) limits as long as the
drug was administered as labeled (every 8 to 12 hours).
Over the past decade, once-daily dosing of aminoglycoside
antibiotics (such as gentamicin) has come into vogue.
Considering the cost savings, potentially increased effica-
cy, and reduced toxicity associated with once-daily dos-
ing,3 it logically follows that this dosing schedule would
become a preferred approach, though not approved by the
FDA. Even though the endotoxin contamination of the
gentamicin was below USP limits and thus below the FDA-
enforceable limit of 1.7 endotoxin units per milligram,
peak systemic endotoxin concentrations in these patients
often surpassed the pyrogenic threshold of 5 endotoxin
units per kilogram of body weight when gentamicin (5 to
7 mg per kilogram per day) was infused as a single dose,1
and hence the deluge of reported adverse reactions.
Gentamicin has been a nonproprietary product for near-
ly 20 years. Therefore, pharmaceutical firms have no mon-
etary impetus to petition for approval of once-daily dosing
of gentamicin. If approval were granted, the USP would
set a new upper limit for endotoxin in parenteral gentami-
cin preparations.
As an “off-label” use, once-daily dosing of aminoglyco-
sides containing deleterious contaminants, such as endo-
toxin, presents formidable challenges for the FDA and for
practitioners, as well as for patients. An interesting turn in
an already twisted story relates to the FDA Modernization
Act of 1997, according to which off-label uses of drugs
may be promoted. This contrasts with the FDA’s previous-
ly conservative position, forbidding pharmaceutical manu-
facturers from announcing nonapproved uses. This leaves
us with the inevitable question: who is financially, ethical-
ly, and morally responsible for damage caused by endotox-
in from gentamicin (or gentamicin misuse)? The FDA says
that Fujisawa was acting within the law. Is the FDA acting
within the law? Are we? Potential uses certainly outnum-
ber the thousands of drugs that constitute the pharmaceu-
tical armamentarium in the United States. Undoubtedly,
these issues will arise again.
On November 30, 1998, Fujisawa voluntarily withdrew
all unexpired 40-mg-per-milliliter preparations of parenteral
gentamicin, as a gesture of good faith. This was not an FDA-
forced recall, since no current laws or regulations had been
violated. It is noteworthy that Fujisawa recently sold the
injectable-drug division that manufactured gentamicin.
JIM A. KRIEGER, R.PH., PH.D.
LAMAR DUNCAN, M.S., R.PH.
University of New Mexico Health Sciences Center
Albuquerque, NM 87131
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Case 35-1998: Use of Lithium to Prevent 
Corticosteroid-Induced Mania
To the Editor: I was surprised to read that a physician
caring for the patient described in Case 35-1998 (Nov. 19
issue)1 administered lithium to prevent corticosteroid-
induced manic symptoms. No reference was given for this
intervention, and lithium itself can cause central nervous
system side effects. Several reviews of the central nervous
system side effects of corticosteroids mention the possible
value of the prophylactic administration of lithium.2-4 These
reviews all cite the same study,5 an interesting report on
the effects of lithium in a cohort of patients treated with
corticotropin for multiple sclerosis. In this study, lithium-
treated patients were compared with a historical control
group of patients who had similar medical problems and
treatment. The lithium-treated patients had no severe psy-
chiatric symptoms. One definite and one possible case of
lithium intoxication occurred. The investigators also noted
substantial variation in lithium levels and used a twice-
weekly monitoring program to achieve control. Fourteen
percent of the historical control patients had psychological
side effects severe enough to require termination of corti-
costeroid therapy or intervention with antipsychotic drugs.
That study, by Falk et al.,5 suggests possible benefits and
risks of the lithium intervention. However, the nature of
the study, which used historical controls rather than ran-
dom allocation of patients, limits the value of the obser-
vations. The authors were appropriately careful in their
recommendations concerning their findings. They com-
ment that lithium “prophylaxis” might be warranted for
patients who have previously had adverse effects during
treatment with corticosteroids, but they did not recom-
mend routine prophylaxis for any patient group.
Thus, the literature does not appear to support routine
lithium therapy “in anticipation of the development of
manic symptoms.”1 Patients who become manic during
corticosteroid therapy should be treated for mania if cor-
ticosteroid therapy must be continued. The use of lithium
might be considered for patients who have previously had
mood disorders while taking corticosteroids.
WILLIAM MERRILL, M.D.
New Orleans Veterans Affairs Medical Center
New Orleans, LA 70112
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Hallux Rigidus and Atrophy of Calf Muscles
To the Editor: Unilateral calf swelling is abnormal and a
cardinal manifestation of deep-vein thrombosis. The find-
ing of asymmetry of the circumference of the two calves
may lead to an extensive and occasionally invasive workup
to rule out this potential cause of pulmonary embolism.
A 52-year-old woman who was being evaluated for non-
specific arthralgias noted that a recently purchased pair of
knee-high boots was loose on one leg. Physical examina-
tion revealed a 2-cm difference in calf circumference at a
point 15 cm below the insertion of patella, with no other
abnormalities except for unilateral hallux rigidus on the
smaller side. Hallux rigidus is a term used to describe re-
stricted dorsiflexion of the metatarsophalangeal joint of
the great toe related to dorsal osteophytes that restrict mo-
tion. These osteophytes are easily palpable on physical ex-
amination and may develop as a result of osteoarthritis or
as a reaction to prior inflammatory arthritis. When symp-
tomatic, hallux rigidus produces pain in the metatarsopha-
langeal joint that is related to activity. It was hypothesized
that lack of dorsiflexion in the great toe led to atrophy of
the gastrocnemius in the affected leg and the appearance
of calf swelling in the unaffected leg.
To test this hypothesis, more than 1000 consecutive pa-
tients in a general rheumatology practice were examined
during the next year for the presence of unilateral hallux
rigidus, as determined by a finding of passive dorsiflexion
of the first metatarsophalangeal joint of less than 30 de-
grees on one side and of more than 60 degrees on the un-
affected side. Seventeen patients met this criterion. Each
had between 1 and 2.5 cm of atrophy in the affected calf
at a point 15 cm below the insertion of the patellar ten-
don. In none was great-toe pain the primary symptom at
presentation. Twenty-five control patients were examined
by the same technique, and none had a difference in cir-
cumference between the two sides of more than 0.5 cm.
Unilateral hallux rigidus is a common condition that
can produce atrophy of the calf musculature in the affect-
ed leg, creating the appearance of swelling in the other
leg. It should be considered along with a ruptured Baker’s
cyst as one of the rheumatologic conditions that may be
manifested as the syndrome of “pseudophlebitis.”1
RONALD J. ANDERSON, M.D.
Brigham and Women’s Hospital
Boston, MA 02115
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Large Hepatic Hematoma and Intraabdominal 
Hemorrhage Associated with Abuse of Anabolic 
Steroids
To the Editor: Hepatocellular neoplasms, peliosis hepatis,
and hepatic necrosis have been reported to be complications
of long-term therapy with androgenic anabolic steroids.1
We report a case of a large subcapsular hepatic hematoma
and subsequent intraabdominal hemorrhage associated
with the abuse of anabolic steroids by a bodybuilder.
A 24-year-old man was admitted to the hospital with
right-upper-quadrant pain, mild tachycardia, hypertension,
and oliguria. The patient reported a 23-month history of
polydrug abuse to enhance the results of his bodybuilding
exercises. He had been taking mesterolone (50 mg) daily
and nandrolone (400 mg), clomiphene (50 mg), and cho-
rionic gonadotropin (1250 IU) weekly. The patient report-
ed no history of abdominal trauma. The serum aspartate
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aminotransferase level was 295 U per liter, and the serum
alanine aminotransferase level was 927 U per liter, with
normal levels of total bilirubin, alkaline phosphatase, and
g-glutamyltransferase. Abdominal computed tomography
(Fig. 1) showed a large subcapsular hematoma of the right
liver lobe measuring 20 by 8 by 19 cm. The patient’s con-
dition was stabilized, and he was observed in the intensive
care unit. An abdominal sonogram showed more than 1.5
liters of free fluid in the abdominal cavity, and rapid sur-
gical exploration was necessary. The macroscopic appear-
ance of the affected hepatic region and the histologic re-
sults of the biopsies showed extensive hepatic necrosis with
no atypical or malignant cells.
Coronary artery disease,2 thromboembolic complica-
tions,3 and intraabdominal bleeding caused by benign liver
tumors4 are known complications of long-term abuse of
anabolic and contraceptive steroids. This case adds hepatic
subcapsular hematoma to the list.
A recent survey of commercial health clubs in northern
Germany reported that the average dose of nandrolone is
308 mg per week per consumer.5 The maximal dose for
nandrolone should not exceed 50 mg per month, so the
patient had taken more than 30 times the upper therapeu-
tic dosage over a period of 23 months.
JAN SCHUMACHER, M.D.
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Figure 1. Abdominal Spiral Computed Tomography with Con-
trast Enhancement in a Patient with Hepatic Hematoma.
A large hypodense mass can be seen in the right hepatic lobe,
with a size of 20 by 8 cm and a craniocaudal distance of 19 cm.
H denotes subcapsular hematoma, L liver, and K kidney. (Image
courtesy of W. Lotz, M.D., Bad Oldesloe, Germany.)
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